RxDoctor Payments Data

Robert Murphy

Family · Fort Worth, TXNPI 1497855746

Payments from drug & device makers

$416in general payments, 2019–2025

Across 20 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$123
  • Nalu Medical, Inc.$79
  • Sanofi Pasteur Inc.$38
  • Cipher Pharmaceuticals US LLC$35
  • AstraZeneca$35
  • Lilly USA, LLC$34
  • plus $71 from 4 others

What the payments were for

  • Food & beverage$416100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Exact Sciences6$123
Nalu Medical, Inc.3$79
Sanofi Pasteur Inc.2$38
Cipher Pharmaceuticals US LLC1$35
AstraZeneca2$35
Lilly USA, LLC2$34
Phadia US Inc.1$19
GSK1$17
Astellas Pharma US Inc1$17
Gilead1$17

How this compares

$416 in reported general payments places this provider in the 50th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$9,346
Medicare patients
25
Services billed
279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate25$30,309
EliquisApixaban15$17,252
OzempicSemaglutide11$14,355
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$14,027
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$9,227
VascepaIcosapent Ethyl12$3,202
Albuterol Sulfate HfaAlbuterol Sulfate62$1,988
Atorvastatin Calcium187$1,021
Gabapentin49$874
Ventolin HfaAlbuterol Sulfate15$816
Amlodipine Besylate124$695
Metformin Hcl130$689
Omeprazole33$647
Fluticasone Propionate83$644
Levothyroxine Sodium62$626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$17$14,02712 claims
AstraZenecaBreztri Aerosphere$35$9,22714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 15,456 family providers in Texas.

Other family in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →